.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Deloitte
Cerilliant
Harvard Business School
UBS
McKinsey
Johnson and Johnson
McKesson
QuintilesIMS
Julphar

Generated: November 17, 2017

DrugPatentWatch Database Preview

Technetium tc-99m tilmanocept - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for technetium tc-99m tilmanocept and what is the scope of technetium tc-99m tilmanocept freedom to operate?

Technetium tc-99m tilmanocept
is the generic ingredient in one branded drug marketed by Cardinal Health 414 and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Technetium tc-99m tilmanocept has twenty-four patent family members in eleven countries and three supplementary protection certificates in three countries.

There are four drug master file entries for technetium tc-99m tilmanocept. Two suppliers are listed for this compound.

Summary for technetium tc-99m tilmanocept

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cardinal Health 414
LYMPHOSEEK KIT
technetium tc-99m tilmanocept
INJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Cardinal Health 414
LYMPHOSEEK KIT
technetium tc-99m tilmanocept
INJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cardinal Health 414
LYMPHOSEEK KIT
technetium tc-99m tilmanocept
INJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Cardinal Health 414
LYMPHOSEEK KIT
technetium tc-99m tilmanocept
INJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Cardinal Health 414
LYMPHOSEEK KIT
technetium tc-99m tilmanocept
INJECTABLE;INJECTION202207-001Mar 13, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: technetium tc-99m tilmanocept

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,545,808Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: technetium tc-99m tilmanocept

Country Document Number Estimated Expiration
Japan2007332380► Subscribe
European Patent Office1178838► Subscribe
Japan5743905► Subscribe
Austria277642► Subscribe
Japan4056701► Subscribe
Canada2750230► Subscribe
Netherlands300736► Subscribe
Japan2015164933► Subscribe
South Korea101713559► Subscribe
Japan2012516328► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TECHNETIUM TC-99M TILMANOCEPT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90025-1Sweden► SubscribePRODUCT NAME: TILMANOCEPT; REG. NO/DATE: EU/1/14/955 20141120
0736Netherlands► SubscribePRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
C0033France► SubscribePRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: EU/1/14/955 20141121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Healthtrust
Colorcon
UBS
McKinsey
Cantor Fitzgerald
Cerilliant
Fuji
AstraZeneca
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot